HFpEF

Re”FINE”ing the role of non steroidal MRAs in Cardio Kidney Metabolic syndrome

Re”FINE”ing the role of non steroidal MRAs in Cardio Kidney Metabolic syndrome

This week, we will discuss non-steroidal mineralocorticoid antagonist in the multiverse of cardiovascular-kidney-metabolic. What FINEHEART pooled analysis would add to what we already learned from FIDELIO-DKD trial?